Publications
Detailed Information
Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Nam-Kyong | - |
dc.contributor.author | Chang, Yoosoo | - |
dc.contributor.author | Choi, Yu Kyong | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | Park, Byung-Joo | - |
dc.date.accessioned | 2012-06-08T07:19:53Z | - |
dc.date.available | 2012-06-08T07:19:53Z | - |
dc.date.issued | 2010-03 | - |
dc.identifier.citation | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY; Vol.19 3; 238-246 | ko_KR |
dc.identifier.issn | 1053-8569 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76913 | - |
dc.description.abstract | Purpose To detect adverse drug reaction (ADR) signals of rosuvastatin compared to other statins with a novel data-mining approach based on relative risk (RR) using the national health insurance claims database, and to evaluate the usefulness of this method as a tool for signal detection. Methods We used the Health Insurance Review & Assessment Service (HIRA) claims database (Seoul, Korea). Serious adverse events (SAE) were defined as any diagnostic code at the time of hospitalization within 12 weeks from a statin prescription date, regardless of causality. Among statin users, RRs were calculated to compare the proportion of rosuvastatin-specific SAE pairs for rosuvastatin users with the corresponding proportion of drug-SAE pairs for users of other statins. Any SAE for which the lower limit of the RR`s 95% confidence interval was greater than 1 was defined as a signal. All detected signals were reviewed to determine whether the signals corresponded with published adverse events (AEs) exclusive to rosuvastatin. Results Among 96236 elderly outpatients who received rosuvastatin, or other statins, from January 2005 to September 2005, 40304 drug-SAE pairs and 376 SAEs were observed. Twenty-five (6.6%) SAEs were detected as signals by the RR-based data-mining approach. Among the 13 references AEs published to be exclusive to rosuvastatin, 8 (61.5%) were found to correspond with the detected signals with a positive predictive value (PPV) of 32%. Conclusions The RR-based data-mining approach successfully detected signals for rosuvastatin using a national health insurance claims database. This approach could be useful for safety surveillance of marketed products. Copyright (C) 2010 John Wiley & Sons, Ltd. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | JOHN WILEY & SONS LTD | ko_KR |
dc.subject | pharmacovigilance | ko_KR |
dc.subject | rosuvastatin | ko_KR |
dc.subject | relative risk | ko_KR |
dc.subject | data-mining | ko_KR |
dc.subject | health insurance claims database | ko_KR |
dc.title | Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 최남경 | - |
dc.contributor.AlternativeAuthor | 장유수 | - |
dc.contributor.AlternativeAuthor | 최유경 | - |
dc.contributor.AlternativeAuthor | 한서경 | - |
dc.contributor.AlternativeAuthor | 박병주 | - |
dc.identifier.doi | 10.1002/pds.1902 | - |
dc.citation.journaltitle | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | - |
dc.description.citedreference | Molokhia M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002522 | - |
dc.description.citedreference | Guthrie RM, 2007, EXPERT OPIN DRUG SAF, V6, P573, DOI 10.1517/14740338.6.5.573 | - |
dc.description.citedreference | Noren GN, 2007, DATA MIN KNOWL DISC, V14, P305, DOI 10.1007/s10618-006-0052-8 | - |
dc.description.citedreference | Choi NK, 2007, ANN PHARMACOTHER, V41, P667, DOI 10.1345/aph.1H247 | - |
dc.description.citedreference | Hauben M, 2007, DRUG SAFETY, V30, P143 | - |
dc.description.citedreference | CHOI NK, 2007, J PREV MED PUB HLTH, V40, P278 | - |
dc.description.citedreference | Alsheikh-Ali AA, 2005, CIRCULATION, V111, P3051, DOI 10.1161/CIRCULATIONAHA.105.555482 | - |
dc.description.citedreference | Almenoff J, 2005, DRUG SAFETY, V28, P981 | - |
dc.description.citedreference | HAUBEN M, 2005, EXPERT OPIN DRUG SAF, V4, P929 | - |
dc.description.citedreference | Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001 | - |
dc.description.citedreference | DuMouchel W, 2004, CLIN THER, V26, P1092 | - |
dc.description.citedreference | Wood L, 2004, DRUG SAFETY, V27, P871 | - |
dc.description.citedreference | Shepherd J, 2003, INT J CLIN PRACT, P27 | - |
dc.description.citedreference | Waller PC, 2003, PHARMACOEPIDEM DR S, V12, P17, DOI 10.1002/pds.773 | - |
dc.description.citedreference | Hauben M, 2003, DRUG SAFETY, V26, P159 | - |
dc.description.citedreference | PARK BJ, 2003, SEOUL NATL U, P19 | - |
dc.description.citedreference | van der Heijden PGM, 2002, STAT MED, V21, P2027, DOI 10.1002/sim.1157 | - |
dc.description.citedreference | van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668 | - |
dc.description.citedreference | Bate A, 2002, DRUG SAFETY, V25, P393 | - |
dc.description.citedreference | Egberts ACG, 2002, DRUG SAFETY, V25, P453 | - |
dc.description.citedreference | Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483 | - |
dc.description.citedreference | Coulter DM, 2001, BRIT MED J, V322, P1207 | - |
dc.description.citedreference | Lindquist M, 2000, DRUG SAFETY, V23, P533 | - |
dc.description.tc | 7 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.